YMAB מזומני החברה ymabs.com

Y-mAbs Therapeutics implements precision antibodies and radioimmunotherapy to combat rare forms of cancer. The size of the cash position confirms financial stability, with the metric holding at 0.06. Revenues are based on the commercialization of Danyelza and the development of the radiopharmaceutical pipeline. High physician confidence underscores the brand's ethical status in the field of pediatric oncology.
פילוחי נתונים אנליטיים מרוכזים עבור Y-mAbs Therapeutics Inc (YMAB)

This indicator captures the aggregate balance of liquid assets at the end of the reporting period, determining the business's ability to promptly meet its obligations. The metric measures the cash reserves available to cover operating expenses without resorting to external financing. For Y-mAbs Therapeutics (YMAB), this resource is critical for maintaining dominance in pediatric immuno-oncology and protecting patent advantages. The trend in high-liquid cash volumes allows for an assessment of the capital burn rate in an environment devoid of price competition.